

Rabbit anti-Human ARID1A Polyclonal Antibody | anti-ARID1A antibody

Anti-ARID1A Antibody, Rabbit Polyclonal

CATALOG #	HOST	REACTIVITY	APPLICATIONS
AAA256609	Rabbit	Human	Immunofluorescence, Immunocytochemistry, Immunohistochemistry, Western Blot

PRODUCT SYNONYMS

ARID1A; Polyclonal Antibody; Anti-ARID1A Antibody; Rabbit Polyclonal; ARID1A Antibody; Rabbit PAb; Antigen Affinity Purified; Anti-B120 Antibody; Anti-BAF250 Antibody; Anti-BAF250a Antibody; Anti-BM029 Antibody; Anti-C1orf4 Antibody; Anti-CSS2 Antibody; Anti-ELD Antibody; Anti-hELD Antibody; Anti-hOSA1 Antibody; Anti-MRD14 Antibody; Anti-OSA1 Antibody; Anti-P270 Antibody; Anti-SMARCF1 Antibody; anti-ARID1A antibody

PRODUCT SPECIFICATIONS

Host	Rabbit
Reactivity	Human
Clonality	Polyclonal
Isotype	Rabbit IgG
Specificity	Human ARID1A
Purity/Purification	Protein A & Antigen Affinity
Form/Format	Liquid; PBS, pH7.0 with 0.03% Proclin300
Applicable Applications for anti-ARID1A antibody	IF (Immunofluorescence), ICC (Immunocytochemistry), IHC (Immunohistochemistry), WB (Western Blot)
Immunogen	E Coli-derived Human ARID1A fragment
Conjugation	Unconjugated
Preparation	Produced in rabbits immunized with E Coli-derived Human ARID1A fragment, and purified by antigen affinity chromatography.
Preparation and Storage	This antibody can be stored at 2-8 degree C for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20 degree C to -80 degree C. Avoid repeated freeze-thaw cycles.

IMAGES



IF (Immunofluorescence)

Immunofluorescence staining of ARID1A in U251MG cells. Cells were fixed with 4% PFA, permeabilized with 0.1% Triton X-100 in PBS, blocked with 10% serum, and incubated with rabbit anti-Human ARID1A polyclonal antibody (dilution ratio 1:1000) at 4 degree C overnight. Then cells were stained with the Alexa Fluor488-conjugated Goat Anti-rabbit IgG secondary antibody (green). Positive staining was localized to Nucleus.



IHC (Immunohistochemistry)

Immunochemical staining of human ARID1A in human rectum with rabbit polyclonal antibody at 1:500 dilution, formalin-fixed paraffin embedded sections.

**IHC (Immunohistochemistry)**

Immunochemical staining of human ARID1A in human brain with rabbit polyclonal antibody at 1:500 dilution, formalin-fixed paraffin embedded sections.

**WB (Western Blot)**

Anti-ARID1A rabbit polyclonal antibody at 1:500 dilution Lane A: HeLa Whole Cell Lysate Lane B: Jurkat Whole Cell Lysate Lysates/proteins at 30 ug per lane. Secondary Goat Anti-Rabbit IgG (H+L)/HRP at 1/10000 dilution. Developed using the ECL technique. Performed under reducing conditions. Predicted band size: 242 kDa Observed band size: 251 kDa

ADDITIONAL INFORMATION**Related Product Information for anti-ARID1A antibody**

The At-rich interactive domain 1A (ARID1A) is frequently mutated in gastric cancers (GCs) with a poor prognosis. Growing evidence indicates that loss of ARID1A expression leads to activation of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway by AKT phosphorylation. ARID1A upregulates its downstream target CDKN1A and suppresses HCC cell proliferation and migration through inhibiting MVIH, that deficiency or loss of functional mutations of ARID1A in HCC cells might contribute to the increased activity of certain cancer-promoting lncRNAs. ARID1A has a dominant role in maintaining chromatin accessibility at enhancers, while the contribution of ARID1B is evident only in the context of ARID1A mutation. ARID1B knockdown in ARID1A mutant ovarian cancer cells causes similar loss of enhancer architecture, suggesting that this is a conserved function underlying the synthetic lethality between ARID1A and ARID1B. In endometriosis, the down-regulated of ARID1A gene was highly correlated with its promoter hyper-methylation. ROS decreased the expression level of ARID1A gene via regulating methylation of its promoter which contributing to the understanding of the pathogenesis of endometriosis. The possible mechanism of ARID1A gene promoter hyper-methylation is ROS up-regulated DNMT1 gene expression. ARID1A promotes tumor initiation in the liver but suppresses metastasis in established tumors. Loss of ARID1A expression enhances radioresistance of pancreatic cancer through activation of PI3K/AKT pathway, which may be a promising target for radiosensitization of ARID1A-deficient pancreatic cancer.

Product Categories/Family for anti-ARID1A antibody

Tumor Suppressors

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com

Online datasheet: <https://stage.aaabiotech.com/polyclonal/arid1a-antibody-immunofluorescence-immunocytochemistry-immunohistochemistry-western-blot-elisa/256609>